Charles River Laboratories International (NYSE:CRL) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded shares of Charles River Laboratories International (NYSE:CRL - Free Report) from a buy rating to a hold rating in a research note released on Saturday.

A number of other equities analysts also recently commented on CRL. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their target price for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Barclays increased their target price on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. Robert W. Baird raised their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Finally, Evercore ISI raised shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target for the company in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Stock Up 3.0%

Charles River Laboratories International stock traded up $4.58 during trading on Friday, reaching $158.48. 752,391 shares of the company's stock were exchanged, compared to its average volume of 1,029,346. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $254.15. The firm has a market cap of $7.78 billion, a price-to-earnings ratio of -243.82, a PEG ratio of 5.21 and a beta of 1.49. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The company's 50-day moving average is $142.30 and its two-hundred day moving average is $152.12.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The firm had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same quarter in the previous year, the business posted $2.27 EPS. The firm's revenue was down 2.7% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Insider Activity

In related news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president owned 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.30% of the stock is owned by company insiders.

Institutional Trading of Charles River Laboratories International

Several large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in Charles River Laboratories International by 15.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company's stock valued at $952,000 after purchasing an additional 817 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Charles River Laboratories International by 13.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock valued at $6,698,000 after acquiring an additional 5,148 shares in the last quarter. GAMMA Investing LLC raised its position in Charles River Laboratories International by 61.6% in the 1st quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company's stock worth $210,000 after purchasing an additional 533 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Charles River Laboratories International by 60.1% during the first quarter. Blue Trust Inc. now owns 2,407 shares of the medical research company's stock valued at $362,000 after acquiring an additional 904 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Charles River Laboratories International by 61.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 459 shares of the medical research company's stock valued at $84,000 after purchasing an additional 175 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).